Dandelion polysaccharide composition with effect of assisting in inhibiting colon cancer and dandelion polysaccharide preparation
By preparing modified dandelion polysaccharide components DRP1 and DRP2, the problem of limited efficacy of dandelion polysaccharides in inhibiting colon cancer in existing technologies has been solved, achieving efficient and safe colon cancer inhibition and inflammation regulation, especially significantly reducing dosage requirements in the inflammation-cancer pathway.
Patent Information
- Application Number
- CN202411059550.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-04
- Publication Date
- 2024-11-15
AI Technical Summary
In the existing technology, the effect of dandelion polysaccharide in adjuvant inhibition of colon cancer is limited, especially in the inflammation-cancer pathway, particularly in inflammatory bowel disease carcinogenesis caused by ulcerative colitis, and requires a large dose of polysaccharide intake to be effective. Moreover, existing studies have not explored the antitumor effects of different polysaccharide components after isolation and purification.
Modified polysaccharide components DRP1 and DRP2 were prepared, including the extraction, separation, purification, and selenization modification of crude dandelion polysaccharide. Small molecule inorganic compounds and oligosaccharides were removed, the bioactivity of the polysaccharide components was improved, and they were prepared into powders, tablets, pills, or liquids.
It effectively inhibits the growth of colon cancer, regulates inflammatory response, reduces dosage, significantly improves biochemical indicators caused by colon inflammation, enhances anti-colon cancer activity, has high safety performance, significantly reduces the expression of pro-inflammatory factors, and improves pathological state.
Smart Images

Figure CN118955751A_ABST
